Search results
Results from the WOW.Com Content Network
Technetium (99m Tc) sestamibi (commonly sestamibi; USP: technetium Tc 99m sestamibi; trade name Cardiolite) is a pharmaceutical agent used in nuclear medicine imaging.The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six (sesta=6) methoxyisobutylisonitrile (MIBI) ligands.
The radioactive properties of 99m Tc can be used to identify the predominant lymph nodes draining a cancer, such as breast cancer or malignant melanoma. This is usually performed at the time of biopsy or resection . 99m Tc-labelled filtered sulfur colloid or Technetium (99mTc) tilmanocept are injected intradermally around the intended biopsy site.
All living cells contain polar molecules and will respond to changes in electric fields. [7] Alternating electric field therapy, or Tumor Treating Fields (TTFields) use insulated electrodes to apply very-low-intensity, intermediate-frequency alternating electrical fields to a target area containing cancerous cells. [7]
Medical research for cancer begins much like research for any disease. In organized studies of new treatments for cancer, the pre-clinical development of drugs, devices, and techniques begins in laboratories, either with isolated cells or in small animals, most commonly rats or mice. In other cases, the proposed treatment for cancer is already ...
Exact Sciences Corp. is an American molecular diagnostics company based in Madison, Wisconsin specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer; in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer.
Andraka talks about his work. Andraka's winning project consisted of a sensor, similar to diabetic test strips, for early-stage pancreatic cancer screening.The sensor, consisting of filter paper coated with single-walled carbon nanotubes and antibodies against human mesothelin, was said to measure the level of mesothelin to test for the presence of cancer in a patient.
Axicabtagene ciloleucel (KTE-C19, ZUMA-3, YESCARTA) was an investigational therapy (for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL)) in which a patient's T cells were genetically modified to express a chimeric antigen receptor designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. [11]
Ludwig Cancer Research is an international community of scientists focused on cancer research, with the goal of preventing and controlling cancer. [1] It encompasses the Ludwig Institute for Cancer Research, an international non-profit organization founded in 1971 by philanthropist Daniel K. Ludwig .